{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:38:23Z","timestamp":1792643903484,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtct.2026.09.010","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:04:43Z","timestamp":1788969883000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Barriers to Patient Referral and Completion of CAR T-Cell Therapy for Relapsed\/Refractory Large B-Cell Lymphoma"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-6562","authenticated-orcid":false,"given":"Mazyar","family":"Shadman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2452-8211","authenticated-orcid":false,"given":"Jenny","family":"Ahlstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta","family":"Nastoupil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0748-8374","authenticated-orcid":false,"given":"David","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2427-0713","authenticated-orcid":false,"given":"Laura","family":"Zitella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Graff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jtct.2026.09.010_bib0001","doi-asserted-by":"crossref","first-page":"77.e1","DOI":"10.1016\/j.jtct.2023.10.017","article-title":"Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: a systematic review and meta-analysis","volume":"30","author":"Jacobson","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"5","key":"10.1016\/j.jtct.2026.09.010_bib0002","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1182\/bloodadvances.2024014164","article-title":"Lisocabtagene maraleucel for relapsed\/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis","volume":"9","author":"Riedell","year":"2025","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2026.09.010_bib0003","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1182\/bloodadvances.2025017120","article-title":"Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium","volume":"10","author":"Wang","year":"2026","journal-title":"Blood Adv"},{"issue":"16","key":"10.1016\/j.jtct.2026.09.010_bib0004","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jtct.2026.09.010_bib0005","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"New Engl J Med"},{"issue":"19","key":"10.1016\/j.jtct.2026.09.010_bib0006","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2026.09.010_bib0007","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.09.010_bib0008","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/10428194.2022.2160200","article-title":"Use of a real-world synthetic control arm for direct comparison of lisocabtagene maraleucel and conventional therapy in relapsed\/refractory large B-cell lymphoma","volume":"64","author":"Van Le","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.010_bib0009","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jtct.2026.09.010_bib0010","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jtct.2026.09.010_bib0011","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.jtct.2026.09.010_bib0012","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"10343","key":"10.1016\/j.jtct.2026.09.010_bib0013","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"The Lancet"},{"issue":"24","key":"10.1016\/j.jtct.2026.09.010_bib0014","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1200\/JCO-25-00399","article-title":"Lisocabtagene maraleucel versus standard of care for second-line relapsed\/refractory large B-cell lymphoma: 3-year follow-up from the randomized, phase III TRANSFORM study","volume":"43","author":"Kamdar","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.09.010_bib0015","series-title":"Poster presented at: ASH Annual Meeting","article-title":"CAR T cell therapy referral patterns and characteristics of patients with relapsed or refractory (R\/R) large B cell lymphoma (LBCL) in the United States","author":"Shadman","year":"2025"},{"key":"10.1016\/j.jtct.2026.09.010_bib0016","first-page":"1","article-title":"Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries","volume":"10","author":"Canales Albendea","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"11","key":"10.1016\/j.jtct.2026.09.010_bib0017","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1182\/bloodadvances.2024013656","article-title":"Impact of vein-to-vein time in patients with R\/R LBCL treated with axicabtagene ciloleucel","volume":"9","author":"Locke","year":"2025","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2026.09.010_bib0018","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jtct.2025.10.025","article-title":"Who is eligible for chimeric antigen receptor T cell therapy? Expert perspectives on overcoming referral barriers","volume":"32","author":"Shadman","year":"2026","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.09.010_bib0019","unstructured":"IQVIA. The path to CAR T-cell therapy: uncovering barriers to patient access. 2025. Accessed December 27, 2025. https:\/\/www.iqvia.com\/locations\/united-states\/library\/white-papers\/the-path-to-car-t-cell-therapy"},{"issue":"18","key":"10.1016\/j.jtct.2026.09.010_bib0020","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1182\/bloodadvances.2024015634","article-title":"Inequalities in CAR T-cell therapy access for US patients with relapsed\/refractory DLBCL: a SEER-Medicare data analysis","volume":"9","author":"Chung","year":"2025","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.jtct.2026.09.010_bib0021","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jtct.2023.08.007","article-title":"Assessing medicaid coverage for hematopoietic cell transplantation and chimeric antigen receptor T cell therapy: a project from the American Society for transplantation and cellular therapy and the National Marrow Donor Program ACCESS initiative","volume":"29","author":"Auletta","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.jtct.2026.09.010_bib0022","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1007\/s12325-021-01838-z","article-title":"Access to chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma","volume":"38","author":"Snyder","year":"2021","journal-title":"Adv Ther"},{"issue":"10","key":"10.1016\/j.jtct.2026.09.010_bib0023","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2217\/imt-2020-0118","article-title":"Perceptions of community hematologists\/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphoma","volume":"12","author":"Gajra","year":"2020","journal-title":"Immunotherapy"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2026.09.010_bib0024","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/blood-2024-209343","article-title":"Barriers to care identified and interventions provided by cancer support community's proactive CAR T navigation program: bridging the gap in patient & caregiver needs","volume":"144","author":"Costello","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2026.09.010_bib0025","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1182\/blood-2024-211499","article-title":"Barriers to CAR-T therapy adoption: comparing access in academic and community settings in the US","volume":"144","author":"Levent","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2026.09.010_bib0026","doi-asserted-by":"crossref","first-page":"1082.e1","DOI":"10.1016\/j.jtct.2024.09.007","article-title":"Real-world analysis of barriers to timely administration of chimeric antigen receptor T cell (CAR T) therapy in diffuse large B-cell lymphoma","volume":"30","author":"Hu","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2026.09.010_bib0027","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"issue":"31","key":"10.1016\/j.jtct.2026.09.010_bib0028","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2017.75.2311","article-title":"Patient-clinician communication: American Society of Clinical Oncology consensus guideline","volume":"35","author":"Gilligan","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2026.09.010_bib0029","doi-asserted-by":"crossref","first-page":"402.e1","DOI":"10.1016\/j.jtct.2024.01.069","article-title":"Communication about chimeric antigen receptor T-cell (CAR-T) therapy","volume":"30","author":"Dhawale","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"suppl 16","key":"10.1016\/j.jtct.2026.09.010_bib0030","article-title":"Web-based patient educational material on chimeric antigen receptor T-cell therapy: quantitative assessment of readability","volume":"41","author":"Thakur","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2026.09.010_bib0031","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1056\/NEJM199707243370411","article-title":"Communicating with patients who cannot read","volume":"337","author":"Weiss","year":"1997","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jtct.2026.09.010_bib0032","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jtct.2023.06.012","article-title":"ASTCT clinical practice recommendations for transplantation and cellular therapies in diffuse large B cell lymphoma","volume":"29","author":"Epperla","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1016\/j.jtct.2026.09.010_bib0033","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"25","author":"Jain","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.010_bib0034","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jtct.2023.10.019","article-title":"If they RECUR, you should refer: a community oncologist patient ID roundtable summary","volume":"30","author":"Riedell","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.jtct.2026.09.010_bib0035","doi-asserted-by":"crossref","first-page":"209.e1","DOI":"10.1016\/j.jtct.2025.10.031","article-title":"National landscape of logistical and nonmedical requirements for transplantation and cellular therapy","volume":"32","author":"Abrams","year":"2026","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2026.09.010_bib0036","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jtct.2024.04.017","article-title":"Chimeric antigen receptor T-cell access in patients with relapsed\/refractory large B-cell lymphoma: association of access with social determinants of health and travel time to treatment centers","volume":"30","author":"Ahmed","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"19","key":"10.1016\/j.jtct.2026.09.010_bib0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers17193216","article-title":"Eliminating REMS for CAR T-cell therapies: an opportunity to improve access","volume":"17","author":"Orosco-Ttamina","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.jtct.2026.09.010_bib0038","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bict.2025.100013","article-title":"Delay in CAR-T from single-case agreements: real-world impact on treatment and outcomes in at least twice-refractory DLBCL","volume":"1","author":"Gromowsky","year":"2025","journal-title":"Blood Immunol Cell Ther"},{"issue":"10","key":"10.1016\/j.jtct.2026.09.010_bib0039","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jtct.2022.07.011","article-title":"Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B cell lymphomas","volume":"28","author":"Riedell","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"10.1016\/j.jtct.2026.09.010_bib0040","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ymthe.2020.10.022","article-title":"Clinical perspective: treatment of aggressive B cell lymphomas with FDA-approved CAR-T cell therapies","volume":"29","author":"Leick","year":"2021","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtct.2026.09.010_bib0041","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.omtm.2023.05.015","article-title":"Medicaid coverage practices for approved gene and cell therapies: existing barriers and proposed policy solutions","volume":"29","author":"Allen","year":"2023","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"22","key":"10.1016\/j.jtct.2026.09.010_bib0042","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T cells and T-cell therapies for cancer: a translational science review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.010_bib0043","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/hematology.2023000472","article-title":"Recognizing, defining, and managing CAR-T hematologic toxicities","volume":"2023","author":"Rejeski","year":"2023","journal-title":"Hematol Am Soc Hematol Educ Prog"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.010_bib0044","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2026.09.010_bib0045","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"issue":"3-4","key":"10.1016\/j.jtct.2026.09.010_bib0046","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1053\/j.seminoncol.2024.02.001","article-title":"CAR T-cell therapy: a collaboration between authorized treatment centers and community oncologists","volume":"51","author":"Bishop","year":"2024","journal-title":"Semin Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2026.09.010_bib0047","doi-asserted-by":"crossref","first-page":"1047.e1","DOI":"10.1016\/j.jtct.2025.08.018","article-title":"The clinical utility of real-time patient-reported outcomes in cell therapy recipients","volume":"31","author":"Meehan","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.jtct.2026.09.010_bib0048","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jtct.2023.06.014","article-title":"Cell therapy informatics: updates on the integration of HCT\/IEC functionalities into an electronic medical record system in the US to promote efficiency, patient safety, research, and data interoperability","volume":"29","author":"Ho","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2026.09.010_bib0049","first-page":"1","article-title":"Patient ambassador support: experiences of the mentorship between newly diagnosed patients with acute leukaemia and their patient ambassadors","volume":"29","author":"N\u00f8rskov","year":"2020","journal-title":"Eur J Cancer Care"},{"issue":"7","key":"10.1016\/j.jtct.2026.09.010_bib0050","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jtct.2023.04.003","article-title":"Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"29","author":"Hoffmann","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2026.09.010_bib0051","first-page":"737","article-title":"Breaking access barriers to autologous stem cell transplantation and chimeric antigen receptor T cell therapy in hematologic malignancies - an ASTCT-NMDP ACCESS initiative","volume":"32","author":"Munshi","year":"2026","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.09.010_bib0052","series-title":"Vision to action blueprint: actions to improve access to CAR T-cell therapy in the US","year":"2026"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672600713X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672600713X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:49:09Z","timestamp":1792640949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672600713X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":52,"alternative-id":["S266663672600713X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.09.010","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Barriers to Patient Referral and Completion of CAR T-Cell Therapy for Relapsed\/Refractory Large B-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}